For Research Use Only. Not for human consumption.
This product is not approved by the FDA for human use. Intended strictly for laboratory research purposes only.
Researched Benefits
Supports significant weight‑loss outcomes
Promotes improved insulin sensitivity and healthier glucose control
Contributes to cardiovascular and liver wellness
Helps increase overall energy expenditure
Retatrutide 10mg is a premium-quality research peptide supplied in lyophilized powder form for laboratory and scientific research applications. Manufactured under strict quality standards, this compound is designed for researchers seeking high-purity peptides for controlled studies and analysis.
This product page is intended solely for educational and research purposes, providing information on compound classification, scientific context, and non‑clinical investigation
Each vial contains 10mg of Retatrutide, carefully prepared to ensure consistency, stability, and reliable research performance.
Important: This product is intended for research purposes only and is not approved for human use.
Retatrutide 10MG is an investigational research peptide developed by Eli Lilly and studied in preclinical and clinical research settings. It functions as a triple agonist, activating GLP‑1, GIP, and glucagon receptors—an approach that allows researchers to explore weight regulation, glucose control, lipid metabolism, and broader metabolic pathways.
The compound is not FDA‑approved and is intended strictly for research use, not medical or therapeutic application. Retatrutide is currently in Phase 3 clinical trials for obesity and type 2 diabetes, where once‑weekly subcutaneous dosing is being evaluated due to its extended half‑life.
Clinical studies have shown substantial weight‑loss effects, with higher doses producing greater reductions in body weight and improvements in metabolic markers. Trial participants on higher doses have achieved over 25% average weight loss across long‑term study periods, along with notable improvements in glucose regulation.
Retatrutide remains an investigational compound and is available only for research purposes.
Studies conducted in controlled research settings have shown that Retatrutide may influence several metabolic pathways, including body‑weight regulation, insulin sensitivity, and glucose management. Research has also observed changes in energy expenditure, liver fat levels, and other metabolic markers.
The most commonly reported side effects in research environments involve gastrointestinal discomfort, such as nausea or vomiting. These effects are typically dose‑dependent and are often reduced in studies through gradual dose escalation and proper injection technique.
Retatrutide is an investigational research compound and is not approved for human or veterinary use. All findings are based on preclinical and controlled research, and the compound should only be handled by qualified professionals following appropriate research‑use guidelines
